Media stories about Spectrum Pharmaceuticals (NASDAQ:SPPI) have trended somewhat positive on Sunday, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Spectrum Pharmaceuticals earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 44.8288583885642 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment’s analysis:
- Spectrum Pharmaceuticals (SPPI) Raised to “Hold” at Zacks Investment Research (americanbankingnews.com)
- Spectrum Pharma Inc (SPPI) Moves 0.11% – Clawson News (clawsonnews.com)
- As Spectrum Pharmaceuticals (SPPI) Share Price Declined, Consonance Capital Management LP Lifted Position … – Hill Country Times (hillcountrytimes.com)
- $33.05 Million in Sales Expected for Spectrum Pharmaceuticals, Inc. (SPPI) This Quarter (americanbankingnews.com)
Shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) opened at $19.42 on Friday. The company has a quick ratio of 4.89, a current ratio of 5.04 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $1,950.00, a P/E ratio of -19.42 and a beta of 1.63. Spectrum Pharmaceuticals has a twelve month low of $4.31 and a twelve month high of $21.95.
A number of analysts recently issued reports on SPPI shares. HC Wainwright reiterated a “buy” rating and issued a $29.00 price target on shares of Spectrum Pharmaceuticals in a report on Monday, December 18th. B. Riley started coverage on Spectrum Pharmaceuticals in a report on Monday, December 18th. They issued a “buy” rating and a $26.00 price target for the company. Guggenheim started coverage on Spectrum Pharmaceuticals in a report on Monday, October 23rd. They issued a “buy” rating and a $32.00 price target for the company. Jefferies Group boosted their price target on Spectrum Pharmaceuticals to $25.00 and gave the company a “buy” rating in a report on Friday, October 20th. Finally, Zacks Investment Research upgraded Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $22.17.
COPYRIGHT VIOLATION NOTICE: This piece was published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.themarketsdaily.com/2018/01/14/spectrum-pharmaceuticals-sppi-given-news-impact-score-of-0-12.html.
Spectrum Pharmaceuticals Company Profile
Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.